Summary
Klotho Neurosciences is a micro-cap biotech company with no revenue and mounting losses. Facing Nasdaq delisting and severe financial distress, its survival depends on near-term financing breakthroughs. The $0.16 share price (April 2025) reflects market skepticism about turnaround prospects.
Bull Case
If Klotho can secure emergency funding and demonstrate clinical progress before August 2025, it might attract acquisition interest from larger biotechs seeking early-stage assets. Successful compliance with Nasdaq could temporarily boost investor confidence.
Bear Case
Likely delisting in August 2025 would destroy remaining shareholder value. With $63.7K cash and $2.07M quarterly losses, bankruptcy appears imminent without immediate capital infusion. Negative equity and unreliable funding make this a high-risk investment.
Recent News
- Facing Nasdaq delisting due to non-compliance with minimum price and market value rules (as of April 2025). Extension granted until August 2025 contingent on meeting milestones. SEC Filing
Financial Analysis
- Revenue: Zero revenue reported across all quarters from Q3 2023 to Q4 2024 (latest data: December 2024).
- Losses: Net losses accelerated to -$6.15M in 2024 vs. -$0.7M in 2023. Q4 2024 net loss was -$2.07M.
- Liquidity: Cash reserves fell from $845K (Q2 2024) to $63.7K (Q4 2024). Current ratio dropped to 0.1265 by December 2024.
- Equity erosion: Stockholders’ equity turned negative (-$1.55M in Q2 2024) before recovering to $1.18M in Q4 2024.
- Negative profitability: EPS of -$0.32 (2024), ROE of -518.87% (2024), and ROIC of -397.62% (2024).
- High risk: Debt-to-equity ratio reached 2.57 in 2023. Price-to-book ratio of 3.57 (April 2025) suggests overvaluation relative to $0.044 book value.
- Liquidity: Current ratio of 0.1265 (Q4 2024) indicates severe short-term liquidity constraints.
The company operates in a capital-intensive biotech sector during global trade instability. Negative beta (-0.024) suggests decoupling from market trends, likely due to micro-specific risks outweighing macro factors. Rising US interest rates (Fed funds rate 4.25-4.50%) compound financing challenges for this pre-revenue firm.
Screener Ratings
Compare over 5500 companies with our screener ratings at AIpha.io.
Overall: 1
Critical financial distress and delisting risk outweigh any speculative biotech potential. Suitable only for high-risk speculators understanding total loss potential.
Value: 1
Negative book value, no revenue, and accelerating losses make fundamental valuation impossible. Current price appears disconnected from financial reality.
Growth: 2
Theoretical growth potential exists in biotech pipelines, but no clinical data or partnerships to support realistic growth prospects.
Dividend: 1
No history of dividends. Capital preservation needs preclude any distribution.
Defensive: 1
Extremely vulnerable to market downturns given liquidity crisis and dependence on equity financing.
Moat: 1
No sustainable competitive advantages evident from financials or disclosures.
S.W.O.T. Analysis
Strengths:
- Nasdaq extension provides temporary lifeline until August 2025
Weaknesses:
- No revenue since at least 2021
- Deteriorating liquidity position
- Negative stockholders’ equity through most of 2024
Opportunities:
- Potential partnership with larger pharma if pipeline shows promise
Threats:
- Imminent delisting risk
- Inability to raise capital in high-rate environment
- Global trade tensions increasing research supply costs
Industry Overview
Threat of New Competitors: Moderate – High R&D costs create barriers, but abundant VC funding in biotech lowers entry thresholds.
Competition Among Existing Firms: High – Crowded neurodegenerative disease space with larger competitors pursuing similar targets.
Suppliers’ Bargaining Power: Moderate – Dependence on specialized research partners/CROs, but multiple providers exist.
Buyers’ Bargaining Power: N/A – No commercial products yet. Future buyers (pharma partners) would have high negotiating power.
Threat of Substitute Products: High – Alternative treatment modalities (gene therapy, small molecules) compete with biologic approaches.
Competitive Advantage
Cost Advantage: None – No commercial scale or proprietary manufacturing.
Intangible Assets: Unclear – No patents or licensing deals disclosed in available data.
Network Effect: None – Early-stage research focus limits ecosystem development.
Switching Costs: None – Preclinical assets don’t create customer lock-in.
Warning: This document has been generated by an advanced customised AI prompted with financial data derived from company filings and other reputable sources. The process is specifically designed to minimise hallucinations, however the output is not 100% reliable. It is essential to check any information in this document before relying on it for financial decisions. You can find the underlying data used here.
Legal Disclaimer
The information contained on this website and associated documents, including all text, data, analyses, opinions, and forward-looking statements, is provided solely for general informational purposes and does not constitute financial, investment, legal, or tax advice. The content has been generated by an artificial intelligence tool using publicly available data and company filings. Although every effort has been made to ensure accuracy, the information is provided “as is” without any warranty—express or implied—of completeness, accuracy, reliability, or suitability for any purpose.
Not Regulated Advice
No FCA Authorization: We are not authorized or regulated by the Financial Conduct Authority (FCA) or any other financial regulatory body to offer investment advice or recommendations. Nothing in this report should be construed as a solicitation, recommendation, or endorsement to buy, sell, or hold any security or financial instrument.
Independent Decision-Making: Investors are strongly encouraged to conduct their own research and consult with a licensed financial advisor or other professional before making any financial decisions. Reliance on the information provided herein is solely at your own risk.
Forward-Looking Statements
This report may contain forward-looking statements, which are based on current expectations, assumptions, and projections that involve risks and uncertainties. Actual results may differ materially from those expressed or implied by these statements. We do not undertake any obligation to update or revise any forward-looking statements in light of new information or future developments.
Limitation of Liability
Under no circumstances shall Aipha.io or its affiliates, employees, or agents be liable for any direct, indirect, incidental, consequential, or other damages arising out of or in connection with the use of, or reliance on, the information contained in this report—even if advised of the possibility of such damages. This includes, without limitation, any loss of profit, revenue, or data.
Use at Your Own Risk
By using this report, you acknowledge that you have read and understood this disclaimer and agree that any reliance on the information provided is at your own risk. [Your Company Name/Aipha.io] expressly disclaims any and all liability for any loss or damage of any kind incurred as a result of any use of this report.